Yissum Research Development Company of the Hebrew University of Jerusalem Ltd.

Other

Hadasit Medical Research Services and Development Ltd.

Ariel-university Research and Development Company Ltd.

Ruth Gallily

Raphael Mechoulam

Aviva Breuer

Esther Shohami

Shimon Slavin

Marc Feldmann

Chaim Lotan

Ester Fride

Lumir Hanus

Lola Weiss

Thea Pugatsch

Yinon Ben Neriah

Michael Zeira

Susana Tchilibon

David Panikashvili

Esther Fride

Anne-Marie Malfait

Arik Moussaieff

Eran Leitersdorf

Vardiella Meiner

Ronen Durst

Compositions that include certain phenyl substituted cyclohexenyl compounds are administered to a subject in a method for treating obesity or an associated disease or disorder or in a method of reducing food consumption or body weight.

Method for treating pain or associated condition or symptom

Cyclohexenyl compounds, compositions comprising them and uses thereof

Use of a cannabidiol for the manufacture of a medicament identified for the treatment or prevention of diabetes and/or insulitis.

Treating or preventing diabetes with cannabidiol

The present invention relates to cannabidiol derivatives and to pharmaceutical compositions comprising cannabidiol derivatives being antiinflammatory agents having analgesic, antianxiety, anticonvulsive, neuroprotective, antipsychotic and anticancer activity. The present invention also relates to a process for the preparation of cannabidiol derivatives. It also relates to the use of cannabidiol derivatives and of pharmaceutical compositions comprising same in the preparation of a medicament, in a method of the treatment of human beings with cannabidiol derivatives or with a pharmaceutical preparations comprising same.

Pharmaceutical compositions comprising cannabidiol derivatives

The present invention relates to 2-arachidonylglycerol (2-AG) to be used as inhibitor of a tumor necrosis factor (TNF-&agr;), in the reduction of edema caused by closed head injury, in the reduction of neurological deficits caused by closed head injury and stroke and in treating pathological conditions caused by TNF-&agr; and/or by radical oxygen intermediates (ROI), in pharmaceutical composition for the same use comprising as active ingredient 2-AG. It comprises also the use of 2-AG and pharmaceutical compositions comprising same in the preparation of a medicament for the treatment of said indications and methods of treatment by 2-AG and pharmaceutical compositions comprising same for diseases caused by said indications.

2-arachidonylglycerol (2-AG)-an inhibitor of tumor necrosis factor-&agr; and neuroprotector of brain in closed head injury

Pharmaceutical compositions are described for preventing TNF toxicity, comprising as active ingredient the stereospecific (&plus;) enantiomer, having (3S,4S) configuration of &Dgr; tetrahydrocannabinol type compounds. The compositions are particularly effective in alleviating and even preventing neurotoxicity due to elevated levels of TNF, including septic shock, cachexia and trauma. They are also effective in the treatment of certain chronic degenerative diseases characterized by TNF production, including autoimmune diseases such as AIDS.

Tumor necrosis factor alpha (TNF-&agr;) inhibiting pharmaceuticals

The application relates to the identification that cannabinoids, such as cannabidiol can be used to treat inflammatory diseases. Cannabinoids for use in treating inflammatory diseases, methods of treating inflammatory diseases and cannabinoids in combination with pharmaceutically acceptable carriers are claimed.

Use of cannabinoids as anti-inflammatory agents

Pharmaceutical compositions are described for preventing TNF toxicity, comprising as active ingredient the stereospecific (&plus;) enantiomer having 3S, 4S configuration of delta 6 tetrahydrocannabinol type compounds. The compositions are particularly effective in alleviating and even preventing neurotoxicity due to elevated levels of TNF, including septic shock, cachexia and trauma. They are also effective in the treatment of certain chronic degenerative diseases characterized by TNF production, including autoimmune diseases.

Tumor necrosis factor .alpha. (TNF-.alpha.) inhibiting pharmaceuticals

Growing community of inventors

Jerusalem, Israel

Ruth Gallily